Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

NCT04836507 is registered in ClinicalTrials.gov with Curocell Inc. as lead sponsor.

NCT NCT04836507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04836507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Curocell Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 2, 2021
Completion date
September 26, 2030
Enrollment
91 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

all (acute b-lymphoblastic leukemia), diffuse large b-cell lymphoma (dlbcl), high-grade b-cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), refractory large b-cell lymphoma, relapsed large b-cell lymphoma, transformed follicular lymphoma (tfl)